Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D I Quinn

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Molecular prognostication in bladder cancer--a current perspectiveM L Quek, D I Quinn, S Daneshmand, et al.
The Journal of Rheumatology|May 1, 1995
Adverse drug reactions and their measurement in the rheumatic diseasesR O Day, D I Quinn, P G Conaghan, et al.
Australian and New Zealand Journal of Medicine|December 1, 1995
Hazards of low dose methotrexateP G Conaghan, D I Quinn, P M Brooks, et al.
Prostate Cancer and Prostatic Diseases|December 16, 2015
Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancerA Barzi, E A Klein, T B Dorff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
The evolution of chemotherapy for the treatment of prostate cancerD I Quinn, H M Sandler, L G Horvath, et al.
International Journal of Oncology|June 15, 2006
Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cellsC Plasencia, E Martínez-Balibrea, A Martinez-Cardús, et al.
Cancer Research|May 15, 1998
Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40C Furger, R J Fiddes, D I Quinn, et al.
Prostate Cancer and Prostatic Diseases|June 14, 2003
Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpressionP Jackson, K Ow, G Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2011
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancerA W Tolcher, D I Quinn, A Ferrari, et al.
Cancer|May 1, 1999
Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experienceM J Veness, D I Quinn, C S Ong, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Molecular prognostication in bladder cancer--a current perspectiveM L Quek, D I Quinn, S Daneshmand, et al.
The Journal of Rheumatology|May 1, 1995
Adverse drug reactions and their measurement in the rheumatic diseasesR O Day, D I Quinn, P G Conaghan, et al.
Australian and New Zealand Journal of Medicine|December 1, 1995
Hazards of low dose methotrexateP G Conaghan, D I Quinn, P M Brooks, et al.
Prostate Cancer and Prostatic Diseases|December 16, 2015
Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancerA Barzi, E A Klein, T B Dorff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
The evolution of chemotherapy for the treatment of prostate cancerD I Quinn, H M Sandler, L G Horvath, et al.
International Journal of Oncology|June 15, 2006
Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cellsC Plasencia, E Martínez-Balibrea, A Martinez-Cardús, et al.
Cancer Research|May 15, 1998
Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40C Furger, R J Fiddes, D I Quinn, et al.
Prostate Cancer and Prostatic Diseases|June 14, 2003
Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpressionP Jackson, K Ow, G Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2011
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancerA W Tolcher, D I Quinn, A Ferrari, et al.
Cancer|May 1, 1999
Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experienceM J Veness, D I Quinn, C S Ong, et al.
Pageof 4